hexamethonium has been researched along with Causalgia Syndrome in 2 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| FOWLER, FD | 1 |
| MOSER, M | 1 |
| ROSE, JC | 1 |
| WEMPLE, JN | 1 |
2 other studies available for hexamethonium and Causalgia Syndrome
| Article | Year |
|---|---|
Use of hexamethonium and dibenzyline in diagnosis and treatment of causalgia.
Topics: Cardiovascular Agents; Causalgia; Hexamethonium; Muscle Relaxants, Central; Neuralgia; Phenoxybenzam | 1956 |
Hexamethonium (C6) in the management of causalgia.
Topics: Bis-Trimethylammonium Compounds; Causalgia; Disease Management; Hexamethonium; Neuralgia | 1951 |